A Study of LM-350 in Subjects With Advanced Solid Tumours
Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.
For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.